- R&D Pipeline
- Season 2 (2021-2030)
| Modality | Indication | Targets | Stage | Company | Project No. | Detail | |
|---|---|---|---|---|---|---|---|
| 1 | Global phase 2 studies of precision medicine based c.MET inhibitor ABN401 | ||||||
| Small Molecules | Solid tumor, NSCLC | c.MET | Phase 2 | Abion Inc. | RS-2023-00284103 | ||
| 2 | Development of a new class of PSMA target radiopharmaceuticals for prostate cancer | ||||||
| Drug-conjugate | Castration-resistant prostate cancer | PSMA | Phase 2 | FutureChem Co., Ltd. | RS-2023-00218051 | ||
| 3 | Development of Novel Radiopharmaceutical for Prostate Specific Membrane Antigen Targeted Therapy | ||||||
| Drug-conjugate | Prostate cancer | PSMA | Phase 2 | CellBion Co., Ltd. | HN21C0626 | ||